Management ChangeJun 30, 2026, 04:12 PM
Xeris Appoints Nerissa Kreher to Board; Shannon Named Chair
AI Summary
Xeris Biopharma Holdings, Inc. announced significant changes to its Board of Directors. The company appointed Dr. Nerissa Kreher as a new Class III director, expanding the Board from seven to eight members, effective July 1, 2026. Additionally, CEO John Shannon was named Chairman of the Board, succeeding Marla Persky, who will transition to the role of Lead Independent Director. Dr. Kreher brings extensive experience as a physician-scientist and biotech executive, particularly in rare diseases.
Key Highlights
- Xeris Biopharma appointed Nerissa Kreher, M.D., to its Board of Directors, effective July 1, 2026.
- The Board expanded from seven to eight members to accommodate Dr. Kreher's appointment.
- John Shannon, CEO, was appointed Chairman of the Board, effective July 1, 2026.
- Marla S. Persky was designated Lead Independent Director, effective July 1, 2026.
- Dr. Kreher received an initial equity award valued at approximately $450,000.
- Dr. Kreher will be eligible for annual equity grants of approximately $300,000.
Price Impact
More from XERS